SG11202104012QA - Antibody formulations - Google Patents
Antibody formulationsInfo
- Publication number
- SG11202104012QA SG11202104012QA SG11202104012QA SG11202104012QA SG11202104012QA SG 11202104012Q A SG11202104012Q A SG 11202104012QA SG 11202104012Q A SG11202104012Q A SG 11202104012QA SG 11202104012Q A SG11202104012Q A SG 11202104012QA SG 11202104012Q A SG11202104012Q A SG 11202104012QA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody formulations
- antibody
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18212591 | 2018-12-14 | ||
| PCT/EP2019/085049 WO2020120730A1 (en) | 2018-12-14 | 2019-12-13 | Antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202104012QA true SG11202104012QA (en) | 2021-05-28 |
Family
ID=64665564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202104012QA SG11202104012QA (en) | 2018-12-14 | 2019-12-13 | Antibody formulations |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220110872A1 (es) |
| EP (1) | EP3893841A1 (es) |
| JP (1) | JP2022512294A (es) |
| KR (1) | KR20210104736A (es) |
| CN (1) | CN113194925A (es) |
| AU (1) | AU2019395841A1 (es) |
| BR (1) | BR112021011399A2 (es) |
| CA (1) | CA3122902A1 (es) |
| IL (1) | IL283886A (es) |
| MX (1) | MX2021007047A (es) |
| SG (1) | SG11202104012QA (es) |
| TW (1) | TWI820270B (es) |
| WO (1) | WO2020120730A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
| CN116643056A (zh) * | 2022-02-15 | 2023-08-25 | 厦门万泰凯瑞生物技术有限公司 | 促甲状腺激素受体复合物、试剂盒、制备方法和用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| WO1998056915A2 (en) | 1997-06-12 | 1998-12-17 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| CA2329940A1 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| JP2008504013A (ja) | 2004-02-06 | 2008-02-14 | モルフォシス・アクチェンゲゼルシャフト | 抗ｃｄ３８ヒト抗体及びその用途 |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| IL296666A (en) | 2005-03-23 | 2022-11-01 | Genmab As | Antibodies against 38cd for the treatment of multiple myeloma |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| RU2425841C2 (ru) | 2005-10-12 | 2011-08-10 | МорфоСис АГ | Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38 |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| PT2580243T (pt) | 2010-06-09 | 2020-01-22 | Genmab As | Anticorpos contra cd38 humana |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| MX360741B (es) | 2011-10-28 | 2018-11-14 | Teva Pharmaceuticals Australia Pty Ltd | Constructos de polipéptidos y sus usos. |
| EP2914302B1 (en) * | 2012-11-05 | 2017-01-04 | MorphoSys AG | Radiolabelled antibody and uses thereof |
| SG11201508923VA (en) | 2013-04-29 | 2015-11-27 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
| KR20230022270A (ko) | 2014-03-28 | 2023-02-14 | 젠코어 인코포레이티드 | Cd38 및 cd3에 결합하는 이중특이적 항체 |
| EA035098B1 (ru) | 2014-07-31 | 2020-04-27 | Санофи | Способ лечения рецидивирующей и/или рефрактерной множественной миеломы |
| TN2017000222A1 (en) | 2014-11-26 | 2018-10-19 | Xencor Inc | Heterodimeric antibodies that bind cd3 and cd38 |
| MY202415A (en) | 2015-11-03 | 2024-04-27 | Janssen Biotech Inc | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| US20170121417A1 (en) * | 2015-11-03 | 2017-05-04 | Janssen Biotech, Inc. | Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses |
| CN108884162A (zh) | 2015-11-10 | 2018-11-23 | 汉堡-埃普多夫大学医学中心 | 针对cd38的抗原结合多肽 |
| JP7402693B2 (ja) * | 2017-05-02 | 2023-12-21 | メルク・シャープ・アンド・ドーム・エルエルシー | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
-
2019
- 2019-12-13 CA CA3122902A patent/CA3122902A1/en active Pending
- 2019-12-13 WO PCT/EP2019/085049 patent/WO2020120730A1/en active Search and Examination
- 2019-12-13 AU AU2019395841A patent/AU2019395841A1/en active Pending
- 2019-12-13 KR KR1020217019371A patent/KR20210104736A/ko unknown
- 2019-12-13 CN CN201980079407.9A patent/CN113194925A/zh active Pending
- 2019-12-13 SG SG11202104012QA patent/SG11202104012QA/en unknown
- 2019-12-13 BR BR112021011399-1A patent/BR112021011399A2/pt unknown
- 2019-12-13 US US17/298,156 patent/US20220110872A1/en active Pending
- 2019-12-13 EP EP19820750.8A patent/EP3893841A1/en active Pending
- 2019-12-13 MX MX2021007047A patent/MX2021007047A/es unknown
- 2019-12-13 TW TW108145802A patent/TWI820270B/zh active
- 2019-12-13 JP JP2021525105A patent/JP2022512294A/ja active Pending
-
2021
- 2021-06-10 IL IL283886A patent/IL283886A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202034901A (zh) | 2020-10-01 |
| BR112021011399A2 (pt) | 2021-09-14 |
| CA3122902A1 (en) | 2020-06-18 |
| US20220110872A1 (en) | 2022-04-14 |
| KR20210104736A (ko) | 2021-08-25 |
| IL283886A (en) | 2021-07-29 |
| WO2020120730A1 (en) | 2020-06-18 |
| MX2021007047A (es) | 2021-10-26 |
| TWI820270B (zh) | 2023-11-01 |
| AU2019395841A1 (en) | 2021-05-20 |
| EP3893841A1 (en) | 2021-10-20 |
| CN113194925A (zh) | 2021-07-30 |
| JP2022512294A (ja) | 2022-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279321A (en) | Anti-SIRPalpha antibody | |
| SG11202106214YA (en) | Novel anti-ccr8 antibody | |
| IL280780A (en) | Anti-TIGIT antibodies | |
| IL279352A (en) | IL-11RA antibodies | |
| IL280013A (en) | Anti-IL36R antibodies | |
| IL278010A (en) | Antibodies to galectin 10 | |
| IL276626A (en) | Formulations of B7-H4 antibody | |
| IL264502A (en) | Anti-CD3 antibody formulations | |
| IL286100A (en) | Formulations of anti-il-36r antibodies | |
| IL281717A (en) | Antibody formulation | |
| IL277030A (en) | Antibodies | |
| GB202110263D0 (en) | Anti-btla antibodies | |
| ZA202101177B (en) | Anti-btla antibody | |
| IL281976A (en) | Formulations of anti-FGFR2 antibody | |
| IL282813A (en) | Formulation of antibodies | |
| GB201811368D0 (en) | Antibody | |
| IL291131A (en) | Formulations of anti-il-23p19 antibodies | |
| IL281594A (en) | Antibodies against KLRG1 | |
| ZA202006263B (en) | Antibody formulation | |
| GB201817172D0 (en) | Antibody | |
| IL283886A (en) | Antibody Formulations | |
| GB201806084D0 (en) | Antibodies | |
| ZA202006262B (en) | Stable antibody formulation | |
| SG11202011823SA (en) | Activator-nucleator formulations | |
| GB201813597D0 (en) | Antibody |